Morgan Stanley Downgrades MapLight Therapeutics to Equal-Weight, Lowers Price Target to $21
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsDowngradesPrice Target
Morgan Stanley analyst Sean Laaman downgrades MapLight Therapeutics (NASDAQ:MPLT) from Overweight to Equal-Weight and lowers the price target from $34 to $21.
Morgan Stanley analyst Sean Laaman downgrades MapLight Therapeutics (NASDAQ:MPLT) from Overweight to Equal-Weight and lowers the price target from $34 to $21.